• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Real ‐world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium–glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score‐matched model analysis in Japan
Risk of CVD using SGLT2Is compared with metformin. AbstractWe aimed to compare the effects of cardiovascular disease risk in Japanese patients with type  2 diabetes on sodium–glucose cotransporter 2 inhibitors (SGLT2Is) or metformin. This retrospective, real-world cohort study was carried out using a claims database and propensity score matching; 58,402 eligible patients (29,201 per group) were included. The outcomes included nonfatal myocardi al infarction, angina pectoris, nonfatal stroke, hospitalization for heart failure and composite end-points. The hazard ratio (HR) for the composite end-point was 0.79, which w...
Source: Journal of Diabetes Investigation - July 31, 2023 Category: Endocrinology Authors: Takeshi Horii, Yoichi Oikawa, Akira Shimada, Kiyoshi Mihara Tags: SHORT REPORT Source Type: research

Prescription patterns and therapeutic effects of second-line drugs in Japanese patients with type 2 diabetes mellitus: Analysis of claims data for metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycemic agents
CONCLUSIONS: Metformin was suggested to have larger effect to reduce death than sulfonylurea in patients receiving first-line DPP4i. The order of first- and second-line for the DPP4i and metformin combination did not affect the outcomes. Given the nature of the study design, certain limitations, including potential under-adjustment for confounders, should be considered.PMID:37096493 | DOI:10.1080/14656566.2023.2206016
Source: Expert Opinion on Pharmacotherapy - April 25, 2023 Category: Drugs & Pharmacology Authors: Rimei Nishimura Tomomi Takeshima Kosuke Iwasaki Sumiko Aoi Source Type: research

Comparison of the effects on cardiovascular events between use of metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycaemic agents in Japanese patients with type 2 diabetes mellitus: a claims database analysis
Conclusions Patients who received metformin as first-line therapy may have reduced cardiovascular events than those receiving DPP-4i. This study conforms to previous Japanese database studies, despite the consideration of its limitation being an observational design.
Source: BMJ Open - March 11, 2022 Category: General Medicine Authors: Nishimura, R., Takeshima, T., Iwasaki, K., Aoi, S. Tags: Open access, Diabetes and Endocrinology Source Type: research

Sodium –glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
In conclusion, SGLT2i initiators had lower risks of cardiovascular events versus other glucose‐lowering drug initiators and, uniquely, versus DPP4i initiators in Japanese real‐world practice.
Source: Journal of Diabetes Investigation - July 25, 2020 Category: Endocrinology Authors: Shun Kohsaka, Masayoshi Takeda, Johan Bodeg ård, Marcus Thuresson, Mikhail Kosiborod, Toshitaka Yajima, Eric Wittbrodt, Peter Fenici Tags: Short Report Source Type: research

SGLT2 inhibitors compared with other glucose ‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
In conclusion, SGLT2i initiators had lower risks of CV events versus oGLD initiators and, uniquely, versus DPP4i initiators in Japanese real‐world practice.
Source: Journal of Diabetes Investigation - June 11, 2020 Category: Endocrinology Authors: Shun Kohsaka, Masayoshi Takeda, Johan Bodegard, Marcus Thuresson, Mikhail Kosiborod, Toshitaka Yajima, Eric Wittbrodt, Peter Fenici Tags: SHORT REPORT Source Type: research

6-Bromoindirubin-3 ′-Oxime (6BIO) Suppresses the mTOR Pathway, Promotes Autophagy, and Exerts Anti-aging Effects in Rodent Liver
In this study, we aimed to investigate the anti-aging effect, and molecular mechanism, of the novel anti-aging drug 6BIO on naturally aged mouse liver. Rapamycin, a well-known promising anti-aging drug that delays aging through mTOR-dependent autophagy (Zhou and Ye, 2018), was used as the positive control in the study. To our knowledge, this is the first study to demonstrate the effects of 6BIO treatment in models of natural aging. Our results indicated that 6BIO ameliorates the decline of liver function with age, including lipid metabolism disorder, and attenuates hepatocyte senescence in aged mice, as revealed by altera...
Source: Frontiers in Pharmacology - April 9, 2019 Category: Drugs & Pharmacology Source Type: research